

## CURRICULUM VITAE

**Alexander M. M. Shepherd**

### GENERAL INFORMATION

#### PERSONAL DATA:

Address: 8452 Fredericksburg Road, #230. San Antonio, TX 78229-3317

Email Address: Clinpharm100@aol.com

#### EDUCATION:

1978	PhD	Clinical Pharmacology	St. Andrews University, Scotland
1972	MRCP (UK)	Internal Medicine Boards	Royal College of Physicians of the UK
1969	M.B, Ch.B.	Medical Degree	St. Andrews University, Scotland
1965	BS	Chemistry and Biochemistry	St. Andrews University, Scotland

#### TRAINING:

1975-1977	Internal Medicine	Dundee Teaching Hospital, Dundee, Scotland Post Doctoral Fellowship
1973-1975	Internal Medicine	Medical Research Council of the UK

#### RESIDENCY:

1969-1972	Internal Medicine	Dundee Teaching Hospital, Dundee, Scotland
-----------	-------------------	--

**ACADEMIC APPOINTMENTS:**

09/2012 - Present	Clinical Professor, Department of Medicine, University of Texas Health Science Center at San Antonio [UTHSCSA], San Antonio, TX
09/1990 - 08/2012	Tenured Professor, Departments of Pharmacology and Medicine UTHSCSA
08/1983 - 08/1990 UTHSCSA	Tenured Associate Professor, Departments of Pharmacology and Medicine UTHSCSA
06/1983 - 08/2012	Member of Graduate Faculty, Department of Pharmacology, UTHSCSA
06/1983 - 08/2012	Chief, Division of Clinical Pharmacology UTHSCSA
06/1982 - 05/1983	Acting Chief, Division of Clinical Pharmacology UTHSCSA, Department of Pharmacology, San Antonio, TX
01/1978 - 07/1983	Assistant Professor, UTHSCSA, Department of Pharmacology, San Antonio, TX
07/1973 - 12/1977	Lecturer in Clinical Pharmacology, University of Dundee, Dundee, UK

**NON-ACADEMIC APPOINTMENTS:**

01/1980 - 12/2010	Consulting Physician	South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, TX
01/1980 - Present	Consulting Physician	University Hospital, San Antonio, TX

**CERTIFICATION AND LICENSURE:**

Description/Agency	Status	Date Acquired	Number	Expiration
American Board of Clinical Pharmacology	Certified	07/1991	91001 (Charter Member)	n/a
General Medical Council of Great Britain	Certified	01/1969	1316010	n/a
ECFMG (Educ Commission for Foreign Medical Graduates)				
ECFMG	Certified	01/1977	284-754-9	n/a
Medicine - Texas State Board of Medical Examiners	Certified	01/1980	F3334	n/a
Foreign Licensing Exam	Certified	01/1979	n/a	n/a
Visa Qualifying Exam	Certified	01/1979	n/a	n/a

## **HONORS AND AWARDS:**

05/2013 Royal College of Physicians of Edinburgh: Elected Fellow

06/2012 American Society for Hypertension: Elected Fellow

06/2011 American Society for Hypertension: Re-elected by Examination, Specialist in Hypertension 2011-2021

11/2010 U.S. Pharmacopeia: vice-chair of the Information Cardiology Expert Committee

01/2009 President's Excellence Teaching Award: Nominated for Teaching award

01/2008 President's Excellence Teaching Award: Nominated for Teaching Award

07/2007 Top 25 ACES Preceptors Award: Presented to the top 25 Student Ward Service Preceptors

06/2004 Medicare Model Guidelines Committee, USP: Elected as Vice Chair

06/2003 Fellow of the Council for High Blood Pressure Research: American Heart Association

06/2002 American Society for Hypertension: Elected as "Specialist in Hypertension"

06/2002 Pharmacology Test Committee for the National Board of Medical Examiners: Elected as member

06/2001 FDA Advisory Committee on Cardiovascular & Renal: Member

06/1997 USP Fellowship: Sponsor of award to Sherri Scott, Pharm.D.

06/1995 UTHSCSA Delegate: United States Pharmacopeia

06/1993 FDA Advisory Committee on Over-the-Counter Drugs: Ad Hoc Member

06/1993 FDA Advisory Committee on Antiviral Agents: Ad Hoc Member

06/1991 Merck Geriatric Clinical Pharmacology Fellow: Sponsor of award to Dean Kellogg, M.D.

06/1988 Merck Geriatric Clinical Pharmacology Fellow: Sponsor of award to Meghan Gerety, M.D.

06/1985 PMAF Developmental Grant for Clinical Pharmacology Units

03/1982 Best Doctors in America: National Edition; 1982-2020

07/1977 Lawrence Bequest Fellowship

12/1976 Pharmaceutical Manufacturers Association Foundation Fellowship in Clinical: Award declined; 1977-1979

07/1976 Lawrence Bequest Fellowship

06/1972 Medical Research Council of Great Britain Clinical Research Fellowship: Clinical Pharmacology 1973–1975.

06/1967 Honors in Chemistry, Botany, Zoology, and Biochemistry: 1967–1968

06/1956 Valedictorian: Rattray School

**PROFESSIONAL DEVELOPMENT:**

Administrative

Date	Description
Annually – present	Certified in; HIPAA compliance, general compliance awareness training, lab safety, blood-borne pathogens, basic information security awareness, privacy online training, biological safety training, conflict of interest,

Clinical

Date	Description
01/01/2013 - present	Journal Club, Division of Hospital Medicine, Focus on clinical issues related to general internal medicine, twice monthly.
01/1978 - present	Grand Rounds, Department of Medicine, Focus on clinical issues related to internal medicine, weekly
01/1981 - present	PHAR4003 Clinical Pharmacology                      Post Graduate    Course Director

Student Contact Hrs: approximately 50; Teach 4th year medical students the clinical pharmacology of medications

**OTHER TEACHING:**

08/1980 - 05/2009            3rd Year Clerkship, UTHSCSA. Lecturer and Clinician. Teach clinical medicine and clinical pharmacology to third year and fourth medical students, pharmacy students, medical interns and residents, approximately 3-5 hours per day for two months per year

01/2003 - 12/2007 High School Students in the Allied Health Course Northeast Independent School District. High school students in the Allied Health Course of the Northeast School District. Several times per year for four years. Teach a variety of subjects, ranging from how to take blood pressure, anatomy of the heart, and basic examination skills.

#### Individual Instruction

01/2013 - Present Mentor 1st and 2nd year medical students, one to two students per year at UTHSCSA

06/1991 - 2017 Review and Supervise Exam of Accreditation American Boards of Clinical Pharmacology

Executive Director of American Boards of Clinical Pharmacology. Develop, review and supervise American Boards of Clinical Pharmacology Exams of Accreditation.

#### **Post-Doctoral Student Supervision**

06/1997 - 06/1998	Long-Shyang Chang	UTHSCSA
06/1994 - 06/1999	Grazia Stagni	UTHSCSA
06/1992 - 06/1994	Dean Kellogg Merck Geriatric Clinical Pharmacology Fellow	UTHSCSA
06/1992 - 06/1994	Matthias Grossmann NATO Scholarship	UTHSCSA
06/1990 - 06/1998	Yan-juan Liu	UTHSCSA
06/1990 - 06/1994	Meghan Gerety Merck Geriatric Clinical Pharmacology Fellow	UTHSCSA
06/1990 - 06/1991	Peter A. Carberry	UTHSCSA
06/1985 - 06/1987	Yi Yang	UTHSCSA
06/1985 - 06/1986	Stephen H. Jackson	UTHSCSA
06/1984 - 06/1987	Chi Ming Kwan	UTHSCSA
06/1984 - 06/1987	Michael J. Jamieson	UTHSCSA
06/1984 - 06/1985	Sadhana Patel	UTHSCSA
06/1984 - 06/1985	Charles C. Bittle	UTHSCSA
06/1982 - 06/1984	Norman A. Irvine Merck International Fellow	UTHSCSA

06/1979 - 06/1982	Min-Shung Lin Taiwan National Scholarship	UTHSCSA
06/1979 - 06/1980	Gary E. Musgrave	UTHSCSA
06/1978 - 06/1979	T. Talseth Merck International Fellow	UTHSCSA
06/1978 - 06/1979	William A. Clementi	UTHSCSA

### Pre-Doctoral Student Supervision

Date	Description	Institution	# Students
06/1982 - 06/1984	Grazia Stagni Served on Ph.D. Committee	UTHSCSA	

### Rotation Student Supervision

Date	Description	Institution	# Students
10/2008 - 11/2008	Erin Vanzant, 3rd year medical student	VA Ward	
10/2008 - 11/2008	Jennifer Bernard, 3rd year medical student	VA Ward	
10/2008 - 11/2008	Nainesh Shah, 3rd year medical student	VA Ward	
03/2008 - 03/2008	Linda Xie, 3rd year medical student	VA Ward	
03/2008 - 03/2008	Molly Dudley, 3rd year medical student	VA Ward	
08/2007 - 05/2008	Steven McMillian	UTHSCSA ACES	

08/2007 - 05/2008	Jessica Flores	UTHSCSA ACES
08/2007 - 05/2008	Duraini Mazen	UTHSCSA ACES
08/2006 - 05/2007	Pearl Kurian	UTHSCSA ACES
08/2006 - 05/2007	Casey Lagan	UTHSCSA ACES
08/2006 - 05/2007	Jeffrey Levea	UTHSCSA ACES
09/2004 - 05/2005	Stan Wright	UTHSCSA ACES
09/2004 - 05/2005	Belinda Hernandez	UTHSCSA
09/2003 - 05/2004	Louis Gutierrez	UTHSCSA
09/2003 - 12/2003	Clifton, Fuller	UTHSCSA ACES
09/2002 - 01/2003	Erik Templeton	UTHSCSA ACES

ACES (Advanced Clinical Evaluation Skills) Second Year Medical students. This course teaches physical diagnosis and methods of obtaining a history and performing a physical examination on a patient. Twenty hours per year

## RESEARCH

### **EXPERTISE:**

Faculty Profile (from Pharmacology Website) - From 1990-2013, the Division of Clinical Pharmacology was based in the Departments of Pharmacology and Medicine and occupied offices and patient and analytical areas in the McDermott Building. The clinical commitment included the Hypertension Service of the University Medical System. Clinical studies were based on this patient population.

### **PROJECTS:**

#### Clinical Trials

09/2011-12/2013      Novartis, A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

07/2010-12/2013 ROCHE, Cardiovascular Outcomes Study to Evaluate the Potential of Alogliptin to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D) ROCHE

05/2008-12/2010 ROCKET -AF, A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation

06/2005-06/2013 CORAL, Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)

06/2005-09/2009 TREAT, Trial to Reduce Cardiovascular Events with Aranesp Therapy; this study is for subjects that have anemia related to chronic kidney disease and who have type 2 diabetes; sponsored by Amgen.

06/2004-04/2010 Accomplish, A Prospective, Multinational, Multicenter, Double Blind, Randomized, Active-Controlled Trial to Compare the Effects of Lotrel (Amlodipine/Benazepril) to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients with High Risk Hypertension; sponsored by Novartis

06/2004-03/2010 Navigator, A Multinational, Randomized, Double-Blind, Placebo-Controlled, Force-Titration, 2x2 Factorial Design Study of the Efficacy and Safety of Long Term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects with Impaired Glucose Tolerance (IGT); sponsored for Novartis.

08/2001-12/2004 AVALON, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled and Open-Label Evaluation of the Safety and Efficacy of Dual Therapy with Atorvastatin plus Amlodipine when Compared to Either Therapy Alone in the Treatment of Patients with Simultaneous Hyperlipidemia and Hypertension. (AVALON)

## **PUBLICATIONS:**

### Published Abstracts

1. Shepherd AM. Control of Hypertension and Other Risk Factors in the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) Clinical Trials 2010 Aug. (ASN 2010).
2. Stevenson IH, O'Malley K, Shepherd AMM. Induction of microsomal enzyme activity by anticonvulsant drugs 2007. p. 386-386. (6th International Congress of Pharmacology; vol. 1975).
3. Bazan C, S Palacio, L Pearce, A Roldan, Talbert R, Bazan C, Shepherd AM. Secondary Prevention of Small Subcortical Strokes (SPS3) pilot trial: Final Results. 2003 Feb. (proceedings from 28th International Stroke Conference).



4. Shepherd AMMS. Efficacy and Safety of Sildenafil Citrate in Patients with Erectile Dysfunction and Diabetes Mellitus Taking Multiple Antihypertensive Agents. 2002. (American Diabetes Association Annual Meeting).
5. Sunthornyothin S, Pool JL, Shepherd AMM, Taylor AA. Blood Pressure Response of Hypertensive Patients to Fenoldopam is Augmented in Non Dippers 1999 May. (American Society of Hypertension Annual Meeting).
6. Bunker N, Liu Y, Neely M, Shepherd AMM, Kellogg Jr DL. ET B receptor control of vascular tone in human hypertension. \*Awarded AFMR Student Research Award; 1999. p. A111. (The FASEB J; vol. 13).
7. Liu Y, Neely M, Shepherd AMM, Kellogg Jr DL. Endothelin A receptor mediated vascular tone is altered with age in women 1999. p. A432. (The FASEB J; vol. 13).
8. Stagni G, Shepherd AMM. Method to assess bioequivalence of topically delivered drug by intradermis microdialysis 1999. p. 123-123. (Clinical Pharmacology & Therapeutics; vol. 65, no. 2).
9. Shepherd AMM, Barnes S, Mosier R. Adverse Drug Reaction Reporting in the South Texas Veterans System 1999.
10. Jamieson MJ, Gonzales GM, Shepherd AMM. Does Ace Inhibition Reverse Hypertensive Resistance Vascular Growth More Than Angiotensin AT1 Antagonism? 1998 Jun. (International Society for Hypertension).
11. Liu YL, Stagni G, Walden JG, Shepherd AMM, Lichtenstein MJ. Thioridazine Dose Related Effects on Biomechanical Force Platform Measures of Sway in Young and Elderly Subjects. 1998. (J Am Ger Soc; vol. 46, no. 431).
12. Stagni G, Liu JY, Kellogg Jr DL, Shepherd AMM. Microdialysis assessment of iontophoretic input rates in human dermis: Current dose proportionality study 1998. (AAPS Meeting).
13. Liu YJ, Kellogg Jr DL, O'Donnell D, Shepherd AM. The contribution of endothelin-A receptor mediated vasoconstriction to basal vascular tone is altered with age in humans 1998. p. 222. (Clin Pharmacol Ther; vol. 63).
14. Kellogg Jr DL, Liu YJ, Doherty DK, O'Donnell D, Shepherd AM. Gender differences in the endothelin B receptor contribution to resting vascular tone in humans 1998. p. A697. (The FASEB J; vol. 12).
15. Stagni G, O'Donnell D, Liu YJ, Kellogg Jr DL, Shepherd AMM. Evaluation of an intradermal microdialysis technique to study transdermal iontophoretic drug delivery in the forearm of human subjects: preliminary results 1997 Nov. p. S-69. (Pharmaceutical Research; vol. Sup14, no. 11).
16. Stagni G, O'Donnell D, Liu YJ, Kellogg Jr DL, Shepherd AMM. Evaluation of the interaction between iontophoretic current and intradermal microdialysis in human forearm skin 1997 Nov. p. S-70. (Pharmaceutical Research (supp); vol. 14, no. 11).

17. Andrew M, Ansell J, Becker D, Becker R, Triplett D, Shepherd AMM. A multicenter trial training oral anticoagulant patients to accurately self test at home 1997 Jun. (Congress of the International Society on Thrombosis and Haemostasis).
18. Kellogg Jr DL, Liu Y, Kosiba IF, Johnson JM, Crandall CG, O'Donnell D, Shepherd AMM. Nitric oxide mediates increases in skin blood flow during local warming in humans. 1997. p. A43. (The FASEB J; vol. 11).
19. Stagni G, Shepherd AMM, Liu YJ, Gillespie WR. Bioavailability assessment from pharmacologic data: method and clinical evaluation 1997. p. 349-362. (J Pharm Biopharm; vol. 25, no. 3).
20. Stagni G, Shepherd AMM, Liu YJ, Gillespie WR. New mathematical implementation of generalized pharmacodynamic models: methods and clinical evaluation 1997. p. 313-348. (J Pharm Biopharm; vol. 25, no. 3).
21. Pool JL, Guthrie RM, Littlejohn T, Raskin P, Shepherd AMM, Weber MA, Weir MR, Wilson TW, Wright JM, deRuyter H, Reeves RA. The Antihypertensive Effects of Irbesartan in Patients With Mild to Moderate Hypertension 1996. p. 152A-152A. (Am J Hypertens; vol. 9, no. 4 pt2).
22. Dooley LE, Liu DH, Stagni G, Jamieson MJ, Shepherd AM, Kellogg Jr DL. Uptake-1 and Cutaneous Vascular Sensitivity to Norepinephrine in Human Hypertension \*Awarded Southern AFMR/SSCI Student Research Award: 1996. p. 67A. (J Investigative Med; vol. 44).
- \* 23. Liu YJ, Kellogg Jr DL, Stagni G, Boyle RO, Shepherd AM. Mechanisms of altered vasoconstriction in human hypertension 1996. p. I-340. (Circulation; vol. 94).
24. Jamieson MJ, Koerth SM, Jackson TI, Romano WF, Tan DX, Skinner MH, Grossmann M, Shepherd AMM. Evaluation of the IITC tail cuff blood pressure recorder by AAMI Criteria 1995 Mar. (American Society for Clinical Pharmacology and Therapeutics Annual Meeting).
25. Stagni G, Shepherd AMM, Liu YJ, Gillespie WR. Bioavailability Assessment from Pharmacologic Data: Method and Clinical Evaluation 1995 Mar. (American Society for Clinical Pharmacology and Therapeutics, 96th Annual Meeting).
26. Liu YJ, Stagni G, Walden JG, Shepherd AMM, Lichtenstein MJ. Comparative Clinical Effects of Thioridazine on Fall Risk on Young and Elderly Subjects. 1995 Mar. (American Society for Clinical Pharmacology and Therapeutics, 96th Annual Meeting).
27. Grossmann M, Kellogg Jr DL, Jamieson MJ, Pergola P, Shepherd AMM. Is the Cutaneous Vascular Response to Acetylcholine Affected by pH Changes Due to DC Iontophoresis? 1995 Mar. (American Society for Clinical Pharmacology and Therapeutics, 96th Annual Meeting).
28. Grossman M, Liu YJ, Stagni G, Jamieson MJ, Tourtellot CL, Garbutt-Sculli LB, Shepherd AMM, Kellogg Jr DL. Uptake 1 and cutaneous vascular sensitivity to norepinephrine in human hypertension 1995. p. I-349. (Circulation; vol. 92).
29. Liu Y, Bennett C, Shepherd AMM, Carberry P, Brodie C. Attenuation of the arteriolar microcirculation in hypertension 1994 Feb. (American Federation for Clinical Research, Southern Section for Clinical Investigation Meeting).

30. Grossmann M, Jamieson MJ, Kellogg Jr DL, Pergola PE, Crandall CG, Shepherd AMM. The effect of iontophoresis on the cutaneous vasculature: evidence for galvanic hyperemia. 1994. p. 255A. (Clin. Res.; vol. 42).
31. Grossmann M, Jamieson MJ, Kellogg Jr DL, Pergola PE, Shepherd AMM. Is there cutaneous vascular tolerance to iontophoresis of sodium nitrite and acetylcholine? 1994. p. 201. (Clin. Pharmacol. Ther.; vol. 55).
32. Jamieson MJ, Romano WF, Ontiveros JA, Shepherd AMM. Wall: Lumen measurements in small mesenteric arteries are influenced by myogenic tone, vessel size and transmural pressure 1994. (4th International Symposium on Resistance Arteries).
33. Stagni G, Shepherd AMM, Liu Y, Gillespie WR. Generalized Pharmacodynamic Modeling: Kinetic characterization and prediction of the cardiovascular effects of verapamil 1994. p. 144-144. (Clin Pharmacol Ther; vol. 55, no. 2).
34. Jamieson MJ, Ontiveros JA, Romano WF, Shepherd AMM. Insensitivity of mesenteric small veins to nitrovasodilators and EDRF 1993 Apr. (British Pharmacological Society).
35. Shepherd AMM. Value of different methods for characterizing cardiovascular drug effects 1993 Apr. (27th Annual Scientific Meeting of the European Society for Clinical Investigation).
36. Grossman M, Jamieson MJ, Kellogg Jr DL, Pergola PE, Shepherd AMM. Cutaneous vascular responses to acetylcholine and sodium nitrite in hypertension. 1993. p. 759A. (Clin Res; vol. 41, no. 4).
37. Carberry PA, Shepherd AMM. Reduced left ventricular mass in essential hypertensive males receiving doxazosin, hydralazine and hydrochlorothiazide 1993. p. 143-143. (Clin Pharmacol Ther; vol. 53, no. 2).
38. Jamieson MJ, Ontiveros JA, Shepherd AMM. Myogenic activity in small veins 1993. p. 138-138. (Clin Pharmacol Ther; vol. 53, no. 2).
39. Shepherd AMM, Carberry PA, Brodie C, Scholler I, Bennett C. Regression and reappearance of vascular structural abnormalities in treated human hypertension 1993. p. 43A-43A. (Am J Hyperten; vol. 63, no. 5 pt2).
40. Shepherd AMM, Carberry PA, Brodie C, Scholler I, Bennett C. Regression of left ventricular mass index (ALVMI) is proportional to the degree of LVH in Hypertension 1993. p. 43A-43A. (Am J Hypertens; vol. 6, no. 5 pt2).
41. Shepherd AMM, Carberry PA, Bennett C, Scholler I, Stevenson IH. Pharmacologic studies of vascular structure and function in hypertension 1992 Jul. (British Pharmacological Society).
42. Carberry PA, Shepherd AMM. Conjunctival arteriolar response to an  $\alpha$  2 adrenergic agonist, para amino clonidine 1992. p. 166-166. (The Pharmacologist; vol. 34, no. 3).
43. Shepherd AMM, Kwan CM, Brodie CL, Jamieson MJ. Determination of alpha-adrenergic blocking potency. 1991 Jan. p. 69-77. (Clin Pharmacol Ther; vol. 49, no. 1).

44. Shepherd AMM, Applegate WB, Shocken D, Schnaper H, Phillips HL, Park G. A randomized trial comparing the efficacy of atenolol, enalapril and diltiazem SR in older hypertensive females 1991. p. 144-144. (Clin Pharmacol Ther; vol. 49, no. 2).
45. Shepherd AMM, Brodie CL, Rico-Penny L, Kwan CM. Determination of alpha adrenergic blocking potency of drugs in humans 1990. p. 209-209. (Clin Pharmacol Ther; vol. 47, no. 2).
46. Shepherd AMM, Kwan CM, Carrillo DW, Brodie CL. Blocking autonomic reflexes does not alter determination of alpha blocking potency of prazosin in humans 1989. p. 131-131. (Clin Pharmacol Ther; vol. 45, no. 2).
47. Shepherd AMM, Kwan CM, Carrillo DW, Brodie CL. Dependence of phenylephrine dose blood pressure responses on autonomic activity in humans 1989. p. 168-168. (Clin Pharmacol Ther; vol. 45, no. 2).
48. Brodie CL, Shepherd AMM, LeForce C, Park G, Hoop R. Determinants of antihypertensive response to diltiazem in systemic hypertension 1989. p. 336A-336A. (Clin Res; vol. 37, no. 2).
49. Schran HF, Shepherd AMM, Choc MM, Gonasun LM, Brodie C. The effect of concomitant administration of isradipine and propranolol on their steady state bioavailability 1989. p. 153-153. (The Pharmacologist; vol. 31, no. 3).
50. Shepherd AMM, Kwan CM, Johnson J, Carrillo DW, Taylor WF. Regional blood flow with prazosin and atenolol in diabetic hypertensives 1988 Jan. p. 38A-38A. (Clin Res; vol. 36, no. 1).
51. Shepherd AMM, Jackson SHD, Rogers D, Ludden TM, Woodworth J, Ludden L, Muir K. Effect of food on blood hydralazine levels in hypertension 1988. p. 147-147. (Clin Pharmacol Ther; vol. 43, no. 2).
52. Shepherd AMM, Brodie CL, Carrillo DW, Kwan CM. Pharmacokinetic interaction between isradipine and propranolol 1988. p. 194-194. (Clin Pharmacol Ther; vol. 43, no. 2).
53. Shepherd AMM, Kwan CM, Carrillo D, Brodie CL. Dependence of phenylephrine dose blood pressure responses on autonomic activity in humans 1988. p. 317A-317A. (Clin Res; vol. 36, no. 3).
54. Shepherd AMM, Yee RW, Yang Y, Rico-Penny L, Brodie C, Comeau P. Pilocarpine induced vasodilator dose responses in conjunctival arterioles 1988. p. 317A-317A. (Clin Res; vol. 36, no. 3).
55. Shepherd AMM, Yee R, Yang Y, Rico-Penny L, Brodie C, Comeau P. Conjunctival arterioles; A model for human cardiovascular research 1988. p. 286-286. (ARVO; vol. 29).
56. Shepherd AMM, Yee RW, Yang Y, Rico-Penny L, Brodie C, Comeau P. Complete vasodilator dose responses on a single human arteriole 1988. p. A164-A164. (The Pharmacologist; vol. 30, no. 3).
57. Jamieson MJ, Jackson SHD, Shepherd AMM, Ludden TM, Woodworth J. Food reduces hydralazine oral bioavailability 1987. p. 174-174. (Clin Pharmacol Ther; vol. 41, no. 2).

58. Shepherd AMM, Davidov M, Valesquez M, Schnaper HW, Carr AA, Hamilton J. PN 200 110: Gradual onset of antihypertensive action? 1987. p. 187-187. (Clin Pharmacol Ther; vol. 41, no. 2).
59. Woodworth JR, Ludden TM, Ludden LK, Shepherd AMM, Rotenberg KS, Graves DA. Controlled release hydralazine: assessments of a possible interaction with potassium chloride 1987. p. S103-S103. (J Pharm Sci; vol. 76).
60. Jamieson MJ, Irvine NA, Jackson SH, Shepherd AMM. Hydralazine hemodynamics in man are not influenced by histamine 1 or 2 antagonism 1986. p. 212A-212A. (Clin Res; vol. 34, no. 1).
61. Jamieson MJ, Patel SS, Shepherd AMM, Jackson SHD, Flanagan PH, Galbraith H. Urapidil's alpha blocking activity in humans 1986. p. 200-200. (Clin Pharmacol Ther; vol. 39, no. 2).
62. Jackson SH, Jamieson MJ, Smith SR, Ludden LK, Ludden TM, Shepherd AMM. Acetylator phenotype in hispanic versus white Americans 1986. p. 640-640. (Fed Proc; vol. 45, no. 3).
63. Jackson SHD, Jamieson MJ, Shepherd AMM, Ludden LK, Ludden TM. Is there a relationship between hydralazine kinetics and age? 1986. p. 98-98. (Acta Pharmacol et Toxicol, Suppl; vol. V).
64. Jamieson MJ, Jackson SHD, Shepherd AMM. The practical analysis of human dose response data 1986. p. 199-199. (Acta Pharmacol et Toxicol, Suppl; vol. V).
65. Jamieson MJ, Patel SS, Shepherd AMM, Jackson SHD, Flanagan PH, Galbraith H. Is urapidil also a beta blocker? 1985. p. 259-259. (The Pharmacologist; vol. 27, no. 3).
66. Steger RW, DePaolo J, Johns A, Shepherd AMM. Hypothalamic neurotransmitter content and in vitro LHRH release in aging male F344 rats 1984 Jan. (Proceedings of the 7th International Congress of Endocrinology).
67. Shepherd AMM, Irvine NA, Ludden TM. Food reduces hydralazine bioavailability and vasodepressor effect 1984. p. 275-275. (Clin Pharmacol Ther; vol. 35, no. 2).
68. Irvine NA, Shepherd AMM, Ludden TM, Johnson JM. Hemodynamic effects of lower body negative pressure 1984. p. 333A-333A. (Clin Res; vol. 32, no. 2).
69. Shepherd AMM, Irvine NA. Participation of the renin angiotensin system (RAS) in cardiac mechanoreceptor modulation of blood pressure 1984. p. 338A-338A. (Clin Res; vol. 32, no. 2).
70. Elfellah MS, Johns A, Shepherd AMM. The effect of age on the binding characteristics of the rat atria to the muscarinic (M) antagonist (3H) quinuclidinyl benzilate (QNB). 1984. p. 214-214. (The Pharmacologist; vol. 26, no. 3).
71. Shepherd AMM, Irvine NA, Lynn MP. Off line non invasive measurement of cardiac output 1983 Sep. p. 98-98. (Proceedings of the 36th ACEMB meeting).
72. McNay JL, Lin MS, Shepherd AMM, Keeton TK. Disproportionate increase in plasma norepinephrine during labetalol induced vasodepression 1983. p. 228-228. (Clin Pharmacol Ther; vol. 33, no. 2).

73. Irvine NA, Shepherd AMM. The effect of age on the antihypertensive response to nitroprusside 1983. p. 487A-487A. (Clin Res; vol. 31, no. 2).
74. Irvine NA, Shepherd AMM. Differential hemodynamic effects of pre and afterload reduction in hypertensive subjects 1983. p. 876A-876A. (Clin Res; vol. 31, no. 5).
75. Shepherd AMM, Irvine NA. Pre and afterload reduction cause differential sympathoadrenal responses in hypertensive patients 1983. p. 877A-877A. (Clin Res; vol. 37, no. 5).
76. McNay JL, Lin M-S, Shepherd AMM, Keeton TK. Disproportionate increase in plasma norepinephrine during labetalol-induced vasodepression 1983. p. 228-228. (Clin. Pharmacol. Ther.; vol. 33).
77. Lin MS, McNay JL, Shepherd AMM, Musgrave GE, Keeton TK. Discordant effects of nitroprusside and hydralazine on heart rate and plasma norepinephrine concentration 1982. p. 244-244. (Clin Pharmacol Ther; vol. 31, no. 2).
78. Ludden TM, Lin MS, Shepherd AMM, McNay JL. Determination of acetylator phenotype in hypertensive patients with renal impairment 1982. p. 245-245. (Clin Pharmacol Ther; vol. 31, no. 2).
79. McNay JL, Lin MS, Shepherd AMM, Keeton TK, Musgrave GE. Persistent elevation of heart rate and plasma norepinephrine following single intravenous doses of hydralazine. 1982. p. 249-250. (Clin Pharmacol Ther; vol. 31, no. 2).
80. Shepherd AMM, Ludden TM, Lin MS, McNay JL. Nonlinearity of plasma hydralazine levels after administration of different doses to hypertensive patients 1982. p. 269-269. (Clin Pharmacol Ther; vol. 31, no. 2).
81. Shepherd AMM, Ludden TM, Lin MS, McNay JL. Hydralazine elimination is saturable after oral but not intravenous administration 1982. p. 258A-258A. (Clin Res; vol. 30, no. 2).
82. Lin MS, McNay JL, Shepherd AMM, Keeton TK. Disproportionate increase in plasma norepinephrine concentration during labetalol induced vasodepression 1982. p. 337A-337A. (Clin Res; vol. 30, no. 2).
83. Shepherd AMM, Green J, Pinkley W, Shapiro S. Safety and efficacy of ST1615, a new antihypertensive agent. 1982. p. 839A-839A. (Clin Res; vol. 30, no. 5).
84. Shepherd AMM, Pinkley W, Lin MS, Keeton TK, McNay JL. The renin angiotensin system does not modulate the vasodepressor response to sodium nitroprusside 1982. p. 873A-873A. (Clin Res; vol. 30, no. 5).
85. Shepherd AMM, Pinkley W, Lin M-S, Keeton TK, McNay JL. The renin-angiotensin system does not modulate the vasodepressor response to sodium nitroprusside 1982. p. 873A-873A. (Clin. Res.; vol. 30).
86. Ludden TM, Shepherd AMM, McNay JL, Lin M-S. Dose independent hydralazine pharmacokinetics after intravenous administration to hypertensive patients 1981. p. 262-262. (Clin Pharmacol Ther; vol. 29, no. 2).

87. Shepherd AMM, Hardin TC, Ludden TM, Miner DJ. Pharmacokinetics of a new B lactam antibiotic, moxalactam 1981. p. 283-283. (Clin Pharmacol Ther; vol. 29, no. 2).
88. Shepherd AMM, Lin MS, Keeton TK, Musgrave GE, McNay JL. Determinants of responsiveness to nitroprusside (NP) infusion in hypertension 1981. p. 360A-360A. (Clin Res; vol. 29, no. 2).
89. Shepherd AMM, Lin MS, Keeton TK, Musgrave GE, McNay JL. Plasma norepinephrine levels as a measure of baroreflex sensitivity in hypertensive man 1981. (Eighth Scientific Meeting of the International Society of Hypertension).
90. Shepherd AMM, Lin MS, Keeton TK, Musgrave GE, McNay JL. Sympathetic responsiveness as a determinant of the degree of hypotension induced by nitroprusside in hypertensive patients 1981. (Eighth Scientific Meeting of the International Society of Hypertension).
91. Shepherd AMM, Lin MS, McNay JL, Musgrave GE. Control mean arterial pressure (CMAP) determines hypotensive response to intravenous vasodilators in hypertension. 1981. (Eighth Scientific Meeting of the International Society of Hypertension).
92. Lin MS, McNay JL, Shepherd AMM, Keeton TK. Adrenergic modulation of the vasodepressor response to intravenous labetalol 1981. p. 323-323. (Circulation; vol. 64, no. 4).
93. Shepherd AM, Lin M-S, Keeton TK, Musgrave GE, McNay JL. Determinants of responsiveness to nitroprusside (NP) infusion in hypertension 1981. p. 360A-360A. (Clin. Res.; vol. 29).
94. Ludden TM, Shepherd AMM, McNay JL. Hydralazine stability 1980 Jul. (Proceedings of Annual Meeting of American Association of Colleges of Pharmacy).
95. Shepherd AMM, Musgrave GE, Badke FR, Walsh T. Tachycardia associated with hydralazine pyruvic acid hydrazone, the major plasma metabolite of hydralazine 1980. p. 1190-1190. (Fed Proc; vol. 39, no. 3).
96. Shepherd AMM, Lin MS, Ludden TM, McNay JL. Acetylator phenotype as a determinant of response to hydralazine (H). 1980. p. 244A-244A. (Clin Res; vol. 28, no. 3).
97. Shepherd AMM, Lin MS, McNay JL, Ludden TM. Determinants of response to intravenous hydralazine in hypertensive patients 1980. p. 817A-817A. (Clin Res; vol. 28, no. 3).
98. Shepherd AMM, McNay JL, Keeton TK, Lin M-S, Musgrave GE. Plasma norepinephrine determines hypotensive responsiveness to nitroprusside in hypertension 1980. p. 827A-827A. (Clin Res).
99. Shepherd AMM, Lin MS, Ludden TM, McNay JL. Acetylator phenotype as a determinant of response to hydralazine (H). 1980. (7th Scientific Meeting of the International Society of Hypertension).
100. Ludden TM, Shepherd AMM, Lin MS, McNay JL. Hydralazine (H) pharmacokinetics in hypertensive patients following intravenous administration 1980. (World Conference on Clinical Pharmacology and Therapeutics).

101. Shepherd AMM, Ludden TM, Lin MS, McNay JL. Hydralazine (H) disposition in hypertensive patients 1980. (World Conference on Clinical Pharmacology and Therapeutics).
102. Ludden TM, Shepherd AMM, Lin MS, McNay JL. Pharmacokinetics of hydralazine following intravenous administration to hypertensive patients 1980. p. 268-268. (Clin Pharmacol Ther; vol. 27, no. 2).
103. Shepherd AMM, Ludden TM, Lin MS, McNay JL. Hydralazine disposition in hypertensive patients 1980. p. 286-286. (Clin Pharmacol Ther; vol. 27, no. 2).
104. Hewick DS, Shepherd AMM, Stevenson IH, Wilson NM. Pharmacokinetics of vitamin K in young and aged rats 1980. p. 310p-311p. (Br J Pharmacol; vol. 69).
105. Ludden TM, Goggin LK, Haegele KD, Shepherd AMM, McNay JL. A specific high performance liquid chromatographic assay for hydralazine in human plasma 1979. p. 268-268. (Fed Proc; vol. 38, no. 3).
106. McNay JL, Goggin LK, Haegele KD, Ludden TM, Shepherd AMM, Skrdkant HB, Talseth T, Clementi WA. The pharmacokinetics and pharmacodynamics of hydralazine and hydralazine hydrazones 1979. p. 36-36. (Archivos Venezolanos de Cardiologia; vol. VI).
107. Talseth T, Shepherd AMM, McNay JL, Skrdlant HB, Haegele KD, Clementi WA, Ludden TM. Mechanisms of low renal clearance of hydralazine pyruvic acid hydrazone (HPH) in man 1979. p. 238A-238A. (Clin Res; vol. 27, no. 2).
108. Shepherd AMM, Clementi WA, Haegele KD, Ludden TM, McNay JL, Skrdkant HB, Talseth T. In vivo and in vitro effects of hydralazine pyruvic acid hydrazone (HPH). 1979. p. 317A-317A. (Clin Res; vol. 27, no. 2).
109. Shepherd AMM, Haegele KD, Ludden TM, Talseth T, Clementi WA, McNay JL. Hydralazine disposition following a single oral dose in human volunteers 1979. p. 318A-318A. (Clin Res; vol. 27, no. 2).
110. Shepherd AMM, Lin MS, Ludden TM, McNay JL. Relationships between plasma hydralazine (H) concentrations and hypotensive response in patients 1979. p. 738A-738A. (Clin Res; vol. 27, no. 2).
111. Shepherd AMM, Stevenson IH. Warfarin protein binding in young and elderly subjects 1978. p. 129-129. (Clin Pharmacol Ther; vol. 23, no. 1).
112. Haegele KD, Clementi WA, Shepherd AMM, de Vicuna A, de Vicuna N, McNay JL. Metabolism of hydralazine (I hydrazinophthalazine): Identification and properties of active metabolites 1978. (Proceedings of the 5th International Symposium on Mass Spectrometry in Biochemistry and Medicine).
113. Shepherd AMM, Salem SAM, Rajjayabun P, Stevenson IH. Induction of drug metabolism in the elderly 1978. p. 295A-295A. (Clin Res; vol. 26, no. 1).
114. Shepherd AMM, Clementi WA, Haegele KD, Ludden TM, McNay JL, Skrdkant HB, Talseth T. In vivo and in vitro effects of hydralazine (H) and hydralazine pyruvic acid hydrazone (HPH). 1978. p. 782A-782A. (Clin Res; vol. 26, no. 1).



115. Shepherd AMM, Wilson NM, Stevenson IH. Vitamin K pharmacokinetics: Response in young and elderly patients. 1977. p. 117-117. (Clin Pharmacol Ther; vol. 21).
116. Shepherd AMM, Emslie-Smith D, Stevenson IH. Antipyrine elimination in patients with hypothermia 1976. p. 958-959. (Br J Clin Pharmacol; vol. 3).
117. Shepherd AMM, Brown Y, Christopher L, Henney C, Stevenson IH. Factors influencing anticoagulant control in outpatients 1976. p. 86-86. (Scott Med J; vol. 21).
118. Manns JJ, Shepherd AMM, Isles TE, Adamson DG, Crooks J. Assessment of a new index of end organ function in hypothyroidism 1976. p. 22p-22p. (Clin Sci Mol Med; vol. 51).
119. Shepherd AMM, Stevenson IH. Sensitivity to warfarin sodium following acute myocardial infarction 1976. p. 347-348. (Br J Clin Pharmacol; vol. 3).
120. Hewick DS, Moreland TA, Shepherd AMM, Stevenson IH. The effect of age on the sensitivity to warfarin sodium 1975. p. 189-190. (Br J Clin Pharmacol; vol. 2).
121. Hewick DS, Moreland TA, Shepherd AMM, Stevenson IH. The effect of age on sensitivity to and handling of warfarin sodium 1975. p. 13p-13p. (Clin Sci Mol Med; vol. 49).

## Book Chapters

1. Shepherd AM. Nitrates, Dopamine Agonists, Potassium channel Openers, And Serotonin-Related Agents In: Joseph L. Izzo Jr., MD/Domenic A Sica, MD/Henry R. Black, MD. Hypertension Primer The Essentials of High Blood Pressure Fourth Edition. Lippincott Williams & Wilkins/Wolters Kluwer; 2008.
- \* 2. Shepherd AM. New and Investigational Drugs for Hypertension In: Henry R. Black, MD and William J. Elliott, MD, PhD. Hypertension A Companion of Braunwald's Heart Disease. Saunders Elsevier; 2007.
3. Shepherd AMM. Pharmacokinetics of Antihypertensive Drugs In: Hypertension: A Companion to Brenner and Rector's the Kidney, Second Edition. Elsevier; 2004.
4. Shepherd AMM. New and Investigational Drugs for Hypertension In: Izzo and White. Hypertension Primer, 3rd Edition. American Heart Association; 2003. p. 440 - 442.
5. Shepherd AM. Other Agents; Potassium Channel Openers, Dopamine Agonists, Serotonin-Related Agents, Renin Inhibitors, Imidazolines, and Endothelin Antagonists In: Joseph L. Izzo, Jr. MD and Henry R. Black, MD. Hypertension Primer The Essentials of High Blood Pressure, Third Edition. Chapter C148- pages 440-441: Lippincott Williams & Wilkins; 2003.
6. Gerety MB, Eimer M, Shepherd AMM. Adverse Drug Reactions and Altered Clinical Pharmacology in the Elderly In: Katz M. Contemporary Management in Internal Medicine. Churchill Livingstone; 1991. p. 43 - 69.

7. Shepherd AMM, Jackson SDH. Vasodilator and Centrally Acting Antihypertensive Agents In: Williams RL, Brater DC, Mordenti J. Rational Therapeutics: A Clinical Pharmacologic Guide for the Health Professional. Marcel Dekker; 1989. p. 425 - 464.
8. Shepherd AMM. Hypertension In: Stein JH. Manual of Internal Medicine: Diagnosis and Treatment. Appleton & Lange; 1988.
9. Shepherd AMM. Physiological Changes with Aging: Relevance to Drug Study Design In: Cutler NR, Narang PK. Drug Studies in the Elderly: Methodological Concerns. Plenum Publishing; 1987.
10. Jamieson MJ, Shepherd AMM. Vasodilators: First or Second Choice Therapy? In: Drayer JIM, Lowenthal DT, Weber MA. Drug Therapy in Hypertension. Marcel Dekker; 1987.
11. Shepherd AMM. Anticoagulant Therapy In: Swift EG. Clinical Pharmacology in the Elderly. Marcel Dekker; 1987.
12. McNay JL, Clementi WA, Groggin LK, Haegele KD, Ludden TM, Shepherd AMM, Skrdlant HB, Talseth T. The pharmacokinetics and pharmacodynamics of hydralazine and hydralazine hydrazones In: Manuel Velasco. Arterial Hypertension. Amsterdam-Oxford-Princeton: International Congress Series 496; 1980.
13. Christopher LJ, Ballinger BR, Shepherd AMM, Ramsay A, Crooks G. A survey of hospital prescribing for the elderly In: Drugs and the Elderly: Perspectives in Geriatric Clinical Pharmacology. MacMillan Press; 1979.
14. Shepherd AMM, Stevenson IH, Wilson N. Warfarin sensitivity in the elderly In: Drugs and the Elderly: Perspectives in Geriatric Clinical Pharmacology. MacMillan Press; 1979.
15. Stevenson IH, Salem SAM, Shepherd AMM. Studies on drug absorption and metabolism in the elderly In: Drugs and the Elderly: Perspectives in Geriatric Clinical Pharmacology. MacMillan Press; 1979.
16. Crooks J, Stevenson IH, Shepherd AMM, Moir DC. The clinical significance and importance of drug interactions In: Grahame-Smith DC. Drug Interactions. Baltimore, MD: University Park Press; 1977.
17. Stevenson IH, O'Malley K, Shepherd AMM. Relative induction potency of anticonvulsant drugs In: Study Group 9 of the IRMMH. Anticonvulsant Drugs and Enzyme Induction. Associated Scientific Publishers; 1976.
18. Shepherd AMM. Hypertension: Principles and Practice In: The Handbook of Hypertension. New York, NY: Marcel Dekker;

## **Monographs**

1. Lam YWF, Shepherd AMM. Perspectives in rational management: Clinical pharmacology I. Cyberlog: The Journal of Applied Medical Software Cardinal Health Systems, Inc.; 1989.

## Editorials

1. Shepherd AMM. A perspective on the American Board of Clinical Pharmacology, Inc. *J Clin Pharmacol* 1990 Dec;30(12):1058-1059.
2. Shepherd AMM. Drug related cognitive impairment *Patient Care* 1981;15:75-75.

## Peer reviewed Journal Articles

- \* 1. Pickering TG, Shepherd AMM, Puddey I, Glasser DB, Orazem J, Sherman N, Mancina G. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. *Am J Hypertens* 2004 Dec;17(12 Pt):1135-1142.
2. Shepherd AMM. A clinical pharmacologist's response to Dr Milton Packer's perspective on the results of the COMET trial. *J Card Fail* 2003 Dec;9(6):454-457.
- \* 3. Stagni G, O'Donnell D, Liu YJ, Kellogg Jr DL, Morgan T, Shepherd AMM. Intradermal microdialysis: kinetics of iontophoretically delivered propranolol in forearm dermis. *J Control Release* 2000 Feb;63(3):331-339.
- \* 4. Taylor AA, Shepherd AMM, Polvino W, Mangoo-Karim R, Ballard K, Sunthornyothin S, Luther RR, Pool JL. Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. *Am J Hypertens* 1999 Sep;12(9 Pt):906-914.
- \* 5. Stagni G, O'Donnell D, Liu YJ, Kellogg Jr DL, Shepherd AMM. Iontophoretic current and intradermal microdialysis recovery in humans. *J Pharmacol Toxicol Methods* 1999 Feb;41(1):49-54.
- \* 6. Tan DX, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, Shepherd AMM. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. *Biochem Biophys Res Commun* 1998 Dec;253(3):614-620.
- \* 7. Liu YJ, Stagni G, Walden JG, Shepherd AMM, Lichtenstein MJ. Thioridazine dose-related effects on biomechanical force platform measures of sway in young and old men. *J Am Geriatr Soc* 1998 Apr;46(4):431-437.
- \* 8. Kellogg Jr DL, Morris SR, Rodriguez SB, Liu Y, Grossman M, Stagni G, Shepherd AMM. Thermoregulatory Reflexes and Cutaneous Active Vasodilation During Heat Stress in Hypertensive Humans *J Appl Physiol* 1998;85(1):175-180.
- \* 9. Oparil S, Kobrin I, Abernethy DR, Levine BS, Reif MC, Shepherd AMM. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. *Am J Hypertens* 1997 Jul;10(7 Pt):735-742.

- \* 10. Jamieson MJ, Gonzales GM, Jackson TI, Koerth SM, Romano WF, Tan DX, Castillon F, Skinner MH, Grossmann M, Shepherd AMM. Evaluation of the IITC tail cuff blood pressure recorder in the rat against intraarterial pressure according to criteria for human devices. *Am J Hypertens* 1997 Feb;10(2):209-216.
- \* 11. Grossmann M, Jamieson MJ, Kellogg Jr DL, Kosiba WA, Pergola PE, Crandall CG, Shepherd AMM. The effect of iontophoresis on the cutaneous vasculature: evidence for current-induced hyperemia. *Microvasc Res* 1995 Nov;50(3):444-452.
- \* 12. Jamieson MJ, Garbutt-Sculli L, Shepherd AMM. Miscompliance by proxy. *Clin Pharmacol Ther* 1995 Nov;58(5):594-594.
13. Shepherd AMM. Value of different methods for characterizing cardiovascular drug effects. *Eur J Clin Invest* 1995 Mar;25 Su:29-34.
- \* 14. Abernethy D, Shepherd AMM, Nierenberg DW. Clinical pharmacologists and health care reform: contributing to the debate. *Clin Pharmacol Ther* 1993 Aug;54(2):123-125.
- \* 15. Carberry PA, Shepherd AMM, Johnson JM. Resting and maximal forearm skin blood flows are reduced in hypertension. *Hypertension* 1992 Sep;20(3):349-355.
- \* 16. Woodworth JR, Ludden TM, Ludden LK, Shepherd AMM, Rotenberg KS. Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challenge. *J Pharm Sci* 1992 Jun;81(6):541-542.
- \* 17. Shepherd AMM, LeForce C, Park GD, Hoop RS, Weir S. The determinants of response to diltiazem in hypertension. *Clin Pharmacol Ther* 1991 Sep;50(3):338-349.
- \* 18. Applegate WB, Phillips HL, Schnaper H, Shepherd AMM, Schocken D, Luhr JC, Koch GG, Park GD. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. *Arch Intern Med* 1991 Sep;151(9):1817-1823.
- \* 19. Jackson SH, Shepherd AMM, Ludden TM, Jamieson MJ, Woodworth J, Rogers D, Ludden LK, Muir KT. Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients. *J Cardiovasc Pharmacol* 1990 Oct;16(4):624-628.
20. Lam YW, Shepherd AMM. Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations. *Clin Pharmacokinet* 1990 Apr;18(4):295-317.
- \* 21. Shepherd AMM, Carr AA, Davidov M, Hamilton J, Schnaper H, Velasquez M, Brockway B, Prisant LM, Hamilton B, Gonasun L. Efficacy and safety of isradipine in hypertension. *J Cardiovasc Pharmacol* 1989 Apr;13(4):580-585.
- \* 22. Kwan CM, Shepherd AMM, Johnson J, Taylor WF, Brockway BA. Forearm and finger hemodynamics, blood pressure control, and lipid changes in diabetic hypertensive patients treated with atenolol and prazosin. A brief report. *Am J Med* 1989 Jan;86(1B):55-58.
- \* 23. Ludden TM, Rotenberg KS, Ludden LK, Shepherd AMM, Woodworth JR. Relative bioavailability of immediate- and sustained-release hydralazine formulations. *J Pharm Sci* 1988 Dec;77(12):1026-1032.

- \* 24. Jamieson MJ, Shepherd AMM, Jackson SH, Patel SS, Flanagan PH, Galbraith H. Alpha adrenergic blocking activity of urapidil in man. *Res Commun Chem Pathol Pharmacol* 1988 Nov;62(2):173-185.
- \* 25. Shepherd AMM. Determinants of antihypertensive response to calcium antagonists in systemic hypertension. *Am J Cardiol* 1988 Oct;62(11):92-96.
- \* 26. Kwan CM, Shepherd AMM, Johnson J, Taylor WF. Forearm and finger hemodynamics, blood pressure control, and lipid changes in patients with diabetic hypertension treated with atenolol and prazosin. *Clin Pharmacol Ther* 1988 Aug;44(2):202-210.
- \* 27. Jackson SH, Jamieson MJ, Johnston A, Shepherd AMM. The analysis of dose-response curves--a practical approach. *Br J Clin Pharmacol* 1987 Feb;23(2):199-205.
- \* 28. Jamieson MJ, Jackson SHD, Patel SS, Shepherd AMM, Flanagan PF, Galbraith H, Stewart W. The assessment of the beta blocking activity of urapidil: a new method *Eur. J. Clin. Pharmacol.* 1986;31:149-154.
- \* 29. Shepherd AMM, Irvine NA. Differential hemodynamic and sympathoadrenal effects of sodium nitroprusside and hydralazine in hypertensive subjects *J. Cardiovasc. Pharmacol* 1986;8(3):527-533.
- \* 30. Elfellah MS, Johns A, Shepherd AMM. The effect of age on the responsiveness of isolated rat atria to carbachol and on binding characteristics of atrial muscarinic receptors *J. Cardiovasc. Pharmacol* 1986;8(4):873-877.
- \* 31. Steger RW, DePaolo LV, Shepherd AMM. Effects of advancing age on hypothalamic neurotransmitter content and on basal and norepinephrine stimulated LHRH release *Neurobiology of Aging* 1985;6:113-116.
- \* 32. Amador A, Steger RW, Bartke A, Johns A, Siler-Khodr TM, Parker Jr R, Shepherd AMM. Testicular LH receptors during aging in Fisher 344 rats *J. Androl* 1985;6:61-64.
- \* 33. Gates GA, Saegert J, Wilson N, Johnson L, Shepherd AMM, Hearne EW. Effect of beta blockade on singing performance *Ann Otol Rhinol Laryngol* 1985;94(6):570-574.
- \* 34. Shepherd AMM, Irvine NA, Ludden TM, Lin MS, McNay JL. Effect of oral dose size on hydralazine kinetics and vasodepressor response. *Clin Pharmacol Ther* 1984 Nov;36(5):595-600.
- \* 35. Irvine NA, Shepherd AMM. Age and blood pressure determine vasodepressor response to sodium nitroprusside *J. Cardiovasc. Pharmacol* 1984 Oct;6(5):816-821.
- \* 36. Shepherd AMM, Irvine NA, Ludden TM. Effect of food on blood hydralazine levels and response in hypertension. *Clin Pharmacol Ther* 1984 Jul;36(1):14-18.
- \* 37. Shepherd AMM, Pinkley W, Lin MS, NcMay JL, Keeton TK. Activation of the renin-angiotensin system by sodium nitroprusside in essential hypertension *J Cardiovasc Pharmacol* 1984;6:201-205.
- \* 38. Irvine NA, Shepherd AMM, Lynn MP. A non-invasive off-line method of measuring cardiac output. *Res Commun Chem Pathol Pharmacol* 1983 Nov;42(2):311-330.

- \* 39. Lin MS, McNay JL, Shepherd AMM, Keeton TK. Effects of hydralazine and sodium nitroprusside on plasma catecholamines and heart rate. *Clin Pharmacol Ther* 1983 Oct;34(4):474-480.
- \* 40. Lin MS, McNay JL, Shepherd AMM, Keeton TK. The response of plasma catecholamines to intravenous labetalol: a comparison with sodium nitroprusside. *Clin Pharmacol Ther* 1983 Oct;34(4):466-473.
- \* 41. Shepherd AMM, Hardin TC, Ludden TM, Miner DJ, Coleman DL. Latamoxef (moxalactam) kinetics in volunteers studied by a specific HPLC assay technique. *J Antimicrob Chemother* 1983 Oct;12(4):377-386.
- \* 42. Ludden TM, Shepherd AMM, McNay JL, Lin MS. Effect of intravenous dose on hydralazine kinetics after administration. *Clin Pharmacol Ther* 1983 Aug;34(2):148-152.
- \* 43. Lin MS, McNay JL, Shepherd AMM, Musgrave GE, Keeton TK. Increased plasma norepinephrine accompanies persistent tachycardia after hydralazine Hypertension 1983;5:257-263.
- \* 44. Shepherd AMM, Lin MS, McNay JL, Musgrave GE, Keeton TK. Baroreflex sensitivity modulates vasodepressor response to nitroprusside Hypertension 1983;5:79-85.
- \* 45. Feely J, McLaren S, Shepherd AMM, Maclean D, Stevenson IH, Swift CG, Isles TE. Antithyroid effect of chlorpropamide? *Hum Toxicol* 1983 Jan;2(1):149-153.
- \* 46. Ludden TM, McNay JL, Shepherd AMM, Lin M-S. Clinical pharmacokinetics of hydralazine *Clin. Pharmacokinet* 1982;7:185-205.
- \* 47. Shepherd AMM, Lin MS, Keeton TK, McNay JL. Plasma noradrenaline as a measure of baroreflex sensitivity in hypertensive man. *Clin Sci (Lond)* 1981 Dec;61 Su:165-168.
- \* 48. Ludden TM, McNay JL, Shepherd AMM, Lin MS. Variability of plasma hydralazine concentrations in male hypertensive patients. *Arthritis Rheum* 1981 Aug;24(8):987-993.
- \* 49. Miner DJ, Coleman DL, Shepherd AMM, Hardin TC. Determination of moxalactam in human body fluids by liquid chromatographic and microbiological methods. *Antimicrob Agents Chemother* 1981 Aug;20(2):252-257.
- \* 50. Shepherd AMM, Lin MS, Keeton TK. Hypoglycemia-induced hypertension in a diabetic patient on metoprolol. *Ann Intern Med* 1981 Mar;94(3):357-358.
- \* 51. Talseth T, McNay JL, Ballinger K, Clementi WA, Shepherd AMM. Vasoconstriction limits to the use of the central ear artery pressure in conscious rabbits. *Lab Anim* 1981 Jan;15(1):1-3.
- \* 52. Shepherd AMM, McNay JL, Ludden TM, Lin M-S, Musgrave GE. Plasma concentration and acetylator phenotype determine response to oral hydralazine. *Hypertension* 1981;3(5):580-585.
- \* 53. Shepherd AMM, Lin MS, McNay JL, Musgrave GE. Determinants of response to intravenous hydralazine in hypertension *Clin. Pharmacol. Ther* 1981;30(6):773-781.
- \* 54. Shepherd AMM, Ludden TM, McNay JL, Lin MS. Hydralazine kinetics after single and repeated oral doses. *Clin Pharmacol Ther* 1980 Dec;28(6):804-811.

- \* 55. Ludden TM, Shepherd AMM, McNay JL, Lin MS. Hydralazine kinetics in hypertensive patients after intravenous administration. *Clin Pharmacol Ther* 1980 Dec;28(6):736-742.
- \* 56. Haegele KD, Skrdlant HB, Talseth T, McNay JL, Shepherd AMM, Clementi WA. Quantitative analysis of hydralazine pyruvic acid hydrazone, the major plasma metabolite of hydralazine. *J Chromatogr* 1980 Jan;187(1):171-179.
- \* 57. Ludden TM, Ludden LK, McNay JL, Skrdlant HB, Swaggerty PJ, Shepherd AMM. Improved assays for hydralazine and hydralazine pyruvic acid hydrazone in human plasma. *Anal. Chem. Acta* 1980;120:297-304.
- \* 58. Talseth T, Haegele KD, McNay JL, Skrdlant HB, Clementi WA, Shepherd AMM. Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone. *J Pharmacol Exp Ther* 1979 Dec;211(3):509-513.
- \* 59. Ludden TM, Goggin LK, McNay JL, Haegele KD, Shepherd AMM. High-pressure liquid chromatographic assay for hydralazine in human plasma. *J Pharm Sci* 1979 Nov;68(11):1423-1425.
- \* 60. Shepherd AMM, Ludden TM, Haegele KD, Talseth T, McNay JL. Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans. *Res Commun Chem Pathol Pharmacol* 1979 Oct;26(1):129-144.
- \* 61. Nicholls DP, Shepherd AMM. Altered warfarin metabolism in iron-deficient patient. *Lancet* 1978 Jul;2(8082):215-216.
- \* 62. Salem SA, Rajjayabun P, Shepherd AMM, Stevenson IH. Reduced induction of drug metabolism in the elderly. *Age Ageing* 1978 May;7(2):68-73.
- \* 63. Christopher LJ, Ballinger BR, Shepherd AMM, Ramsay A, Crooks G. Drug prescribing patterns in the elderly: a cross-sectional study of in-patients. *Age Ageing* 1978 May;7(2):74-82.
- \* 64. Shepherd AMM, Christopher LJ, Henney CR, Brown Y, Stevenson IH. A prospective study of the factors affecting anticoagulant control in a hospital out patient clinic. *Postgrad. Med* 1978;54:784-788.
65. Report by an Ad Hoc Working Group. Minimum information for sensible use of self prescribed medicine. *An International Consensus Lancet* 1977 Nov:1017-1018.
- \* 66. Shepherd AMM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. *Br J Clin Pharmacol* 1977 Jun;4(3):315-320.
- \* 67. Manns JJ, Shepherd AMM, Crooks J, Adamson DG. Measurement of cardiac muscle relaxation in hypothyroidism. *Br Med J* 1976 Jun;1(6022):1366-1368.
- \* 68. Hewick DS, Shepherd AMM. The plasma elimination of the enantiomers of phenprocoumon in man. *J Pharm Pharmacol* 1976 Mar;28(3):257-258.

- \* 69. Stewart WK, Fleming LW, Shepherd AMM. Haemoglobin and serum iron responses to periodic intravenous iron dextran infusions during maintenance haemodialysis *Nephron* 1976;17:121-129.
- 70. Crooks J, Shepherd AMM, Stevenson IH. Drugs and the elderly. The nature of the problem. *Health Bull (Edinb)* 1975 Sep;33(5):222-227.
- \* 71. Evans JR, Shepherd AMM. The effect of desferrioxamine on the colorimetric determination of iron in human serum and plasma. *Clin Chim Acta* 1975 May;60(3):401-404.
- \* 72. Shepherd AMM, Stewart WK, Thjodleifsson B, Wormsley KG. Further studies of gastric hypersecretion in chronic renal failure. *Br Med J* 1974 Jan;1(898):96-98.
- \* 73. Shepherd AMM, Stewart WK, Wormsley KG. Peptic ulceration in chronic renal failure. *Lancet* 1973 Jun;1(7816):1357-1359.

## **Review Articles**

1. Shepherd AM. Direct-Acting Vasodilators *The Journal of Clinical Hypertension* 2011;13(9):690-692.
2. Shepherd AMM. Response to the article by Drs. Eric Brass and Ross Feldman *Clin Pharmacol Ther* 1994;56(2):125-126.
3. Abernethy D, Shepherd AMM, Nierenberg DW. Clinical pharmacologists and health care reform: Contributing to the debate *J Pharmacol Ther* 1993;54(2):123-125.
4. Shepherd AMM, Weidler DJ. The American Board of Clinical Pharmacology, Inc *J Pharmacol Ther* 1993;54(2):117-1228.
5. Shepherd AMM. Book review of *Food, Drugs and Aging Geriatric Medicine Today* 1988;7(3):130-131.
6. Shepherd AMM. Human pharmacology of urapidil *Drugs* 1988;35(6):34-39.
7. Miller RL, Winograd C, Frengley D, Tsukuda RA, Katz P, Barry P, Shepherd AMM, Cooney L. Inpatient Geriatric Consultative Teams *Gerontology & Geriatrics Education* 1988;8(1/2):35-52.
8. Shepherd AMM, Ludden TM. Response to Melander et al: Concomitant food intake does enhance the bioavailability and effect of hydralazine *Clin Pharmacol Ther* 1985;38(4):475-476.
9. Stevenson IH, Shepherd AMM,. Some aspects of drug use and response in the elderly *Br J Clin Pract Supplement - Depression in the Elderly* 1979;33:67-71.



## PRESENTATIONS:

- 04/2017 What should we be lowering blood pressure to now? Results from the Sprint study, presented at the national Cardiorenal conference, San Antonio (Invited Speaker)
- 03/2015 Resistant Hypertension, 38th Annual Family Practice Review Course, Practicing family physicians, UTHSCSA, San Antonio, TX (Invited Speaker)
- 03/2014 Resistant Hypertension, 37th Annual Family Practice Review Course, Practicing family physicians, UTHSCSA, San Antonio, TX (Invited Speaker)
- 03/2013 Resistant Hypertension, 36th Annual Family Practice Review Course, Practicing family physicians, UTHSCSA, San Antonio, TX (Invited Speaker)
- 03/2012 Resistant Hypertension, 35th Annual Family Practice Review Course, Practicing family physicians, UTHSCSA, San Antonio, TX (Invited Speaker)
- 09/2011 Resistant Hypertension, Grand Rounds, UTHSCSA, San Antonio, TX (Invited Speaker)
- 06/2011 Medications and the Older Patient, Summer Institute in Aging Conference, GRECC STVHCS South Texas Geriatric, UTHSCSA, San Antonio, TX (Invited Speaker)
- 03/2011 Resistant Hypertension, 34th Annual Family Practice Review Course, Practicing family physicians, UTHSCSA, San Antonio, TX (Invited Speaker)
- 09/2010 Update on Medical Advisory Panel, VISN 17 Pharmacy Conference, Intended for clinical and administrative pharmacy and medicine leaders as well as physicians and nurses working in the program., Department of Veterans Affairs Employee Education System, Austin, TX (Invited Speaker)
- Details: To plan the direction of VISN 17 pharmacy for 2011 and beyond. Key clinical leaders in pharmacy and medicine from throughout VISN 17 will be presented information and participate in workgroups to develop action plans and goals in their local facilities.
- 06/2010 Medications and the Older Patient, Summer Institute of Aging Conference, GRECC STVHCS South Texas Geriatric, UTHSCSA, San Antonio, TX (Invited Speaker)
- 11/2009 Investigator & Company Responsibility in Drug Development, Fall MSCI Responsible Conduct of Patient Oriented Clinical Research (MEDI 5070), UTHSCSA, San Antonio, TX (Invited Speaker)
- 10/2009 Prescription of Drugs in the Elderly, 9th Annual Fall Preceptor Conference: A Pharmacology Update, Preceptor Conference Nursing School, UTHSCSA, San Antonio, TX (Invited Speaker)
- 06/2009 Pharmacology in Aging Update, 2009 Summer Institute in Aging, GRECC & STVHCS South Texas Geriatric Education, UTHSCSA, San Antonio, TX (Invited Speaker)
- 11/2008 Investigator & Company Responsibility in Drug Development, Fall MSCI Responsible Conduct of Patient Oriented Clinical Research (MEDI 5070), UTHSCSA, San Antonio, TX (Invited Speaker)

06/2008 Medications and the Older Patient, 2008 Summer Institute of Aging, GRECC &STVHCS South Texas Geriatric Education Center, UTHSCSA, San Antonio, TX (Invited Speaker)

11/2007 Medications and the Older Patient, GRECC Geriatric Research Education & Clinical, Faculty, UTHSCSA, San Antonio, TX (Invited Speaker)

06/2007 Medication & the Older Patient: Is Polypharmacy a Problem?, Summer Institute in Aging Conf., GRECC & STVHCS, UTHSCSA, San Antonio, TX (Invited Speaker)

10/2006 Medications in the Older Patient: Is Polypharmacy a Problem?, Sixth Annual Fall Preceptor Conference: A Pharmacology Update, Nursing School, UTHSCSA, San Antonio, TX (Invited Speaker)

06/2006 Medications and the Older Patient, Summer Institute in Aging Conference, GRECC< STVHCS South Texas Geriatric, UTHSCSA, San Antonio, TX (Invited Speaker)

06/2005 Medications in the Older Patient : Is Polypharmacy a Problem?, Fifth Annual Fall Preceptor Conference:, Nursing Group, The University of Texas Health Science Center at San, San Antonio, TX (Invited Speaker)

01/2004 Introduction to Clinical Science, Masters of Science Program, UTHSCSA, San Antonio, TX (Invited Speaker)

01/2004 Vascular Biology Working Group on Heart Failure, FL (Invited Speaker)

01/2004 Symposium on Geriatric Medicine, Veterans Administration System, San Antonio, TX (Invited Speaker)

01/2004 Introduction to Clinical Science, Masters of Clinical Investigation Program, UTHSCSA, San Antonio, TX (Invited Speaker)

**RESEARCH GRANTS:**

Federal

Project #:

Funding Agency: NIH

Title: Cardiovascular Outcomes in Renal Atherosclerotic Lesions

Status: Complete

Period: 06/2005 - 05/2014

Role: Site Principal Investigator % Effort: 10

Total Costs: \$38,000,000.00

Grant Detail:

Project #:

Funding Agency: NIH

Title: Secondary Stroke Prevention in Small Subcortical Strokes

Status: Complete

Period: 06/2002 - 06/2007

Role: Co-Investigator % Effort: 3

Total Costs: \$37,000,000.00

Grant Detail:

Project #:

Funding Agency: NIH

Title: Secondary Stroke Prevention in Small Subcortical Strokes

Status: Complete

Period: 06/2000 - 06/2001

Role: Co-Investigator % Effort: 5

Total Costs: \$1,000,000.00

Grant Detail:

Private

Project #:

Funding Agency: Novartis Pharmaceuticals

Title: NOVARTIS

Status: Complete

Period: 08/2011 - 06/2014

Role: Local Principal Investigator          % Effort: 1

Total Costs: \$284,225.70

Grant Detail: A randomized, double-blind, placebo-controlled, event-drive trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

Project #:

Funding Agency: Hoffmann La ROCHE

Title: ROCHE

Status: Complete

Period: 04/2010 - 03/2014

Role: Local Principal Investigator          % Effort: 1

Total Costs: \$423,864.00

Grant Detail: Cardiovascular Outcomes Study to Evaluate the Potential of Alogliptin to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)

Project #:

Funding Agency: Johnson & Johnson

Title: ROCKET-AF

Status: Complete

Period: 11/2008 - 11/2010

Role: Local Principal Investigator          % Effort: 1

Total Costs: \$594,526.00

Project #:

Funding Agency: Amgen

Title: TREAT, Trial to Reduce Cardiovascular Events with Aranesp Therapy; this study is for subjects that have anemia related to chronic kidney disease and who have type 2 diabetes; sponsored by Amgen.

Status: Complete

Period: 07/2004 - 06/2008

Role: Local Principal Investigator                      % Effort:

Total Costs: \$124,380.00

Project #:

Funding Agency: Novartis Pharmaceuticals

Title: ACCOMPLISH, A Prospective, multinational, multicenter, double-blind, randomized, active-controlled trial (amlodipine/benazepril) to benazepril and hydrochlorothiazide combined...in patients with high risk hypertension.

Status: Complete

Period: 03/2004 - 02/2009

Role: Principal Investigator                      % Effort:

Total Costs: \$297,998.44

Project #:

Funding Agency: Parke Davis Pharmaceuticals

Title: Open Label, Multicenter Study of Clinafloxacin in the Treatment of Infective Endocarditis

Status: Complete

Period: 06/1995 - 05/1999

Role: Local Principal Investigator                      % Effort:

Total Costs: \$20,640.00

Grant Detail: The purpose of this study was to assess the efficacy and safety of clinafloxacin in the treatment of patients with infective endocarditis. Patients stratified on the basis of 1) right-sided versus left-sided endocarditis; 2) native valve versus prosthetic valve infections; and 3) pathogen

recovered from blood cultures. The primary efficacy parameter microbiological eradication rate. Approximately 100 patients enrolled at all sites (5-10 patients per site).

Project #:

Funding Agency: Marion Laboratories

Title: The Effects of TA 3090 Tablets on Systemic and Regional Hemodynamics in Patients with Mild to Moderate Essential Hypertension

Status: Complete

Period: 12/1988 - 05/1990

Role: Local Principal Investigator                      % Effort:

Total Costs: \$50,500.00

**SERVICE**

06/2008- present	University Health System Pharmacy & Therapeutics Committee Member
04/2007-04/2019	Alamo Regional Academy of Science and Engineering Judge
07/2003-12/2006	National Board of Medical Examiners Member
06/2003-06/2006	USMLE Step Pharmacology Testing Material Development Committee Member

**ADMINISTRATIVE RESPONSIBILITIES:**

Dates	Description	Role
05/1964-06/1965	Bute Medical Society	Vice-President

**PATIENT CARE:**

Dates	Type	Description	Role
01/2014-Present	Outpatient	Medical Director Men's Health Program UTHSCSA	Medical Director
01/2012-Present	Outpatient	Executive Health Program UTHSCSA	Medical Director

01/2012-Present	Outpatient	Women's Health Program UTHSCSA	Examining Physician
06/1980-Present	Outpatient	Hypertension Clinic University Hospital, San Antonio, TX	Attending Physician
06/1980-Present	Outpatient	Hypertension Clinic University Physicians Group, San Antonio, TX	Attending Physician
1980-06/2010	Inpatient	Attending Physician Audie Murphy Veterans Hospital, San Antonio, TX	Attending Physician
1980-06/2010	Inpatient	Director of Hypertension Consultation Service University Hospital and Audie Murphy Veterans Administration Hospital, San Antonio, TX	Director
01/1980-06/2010	Outpatient	Hypertension Clinic Audie Murphy Veterans Administration Hospital, San Antonio, TX	Attending Physician

**SERVICE TO GOVERNMENT:**

09/2008-Approx 02/2014      Federal Government      National VA Adverse Drug Event Reporting System Advisory Committee Role: Member Pharmacy Benefits Management (PBM) Services to form this committee pursuant to the request from the Secretary of Veterans Affairs for a broader clinical participation in the monitoring of adverse drug events (ADEs) reported to VA ADERS.

11/2005-11/2010      Federal Government      US Pharmacopeia: Advisory Committee on Cardiovascular Drugs      Member

06/2000-06/2005      Federal Government      US Pharmacopeia; Council of Experts      Chair  
Executive Committee; Chair of Cardiovascular and Renal Information Committee

06/1999- approx 02/2014      Federal Government      Member  
National Medical Advisory Panel to the Pharmacy Benefits Management Program of the Veterans Administration

06/1997-12/2013      Federal Government      Food and Drug Administration  
Consultant

Center for Drug Evaluations and Research

06/1997-06/2010      Federal Government      Ad Hoc Advisory Committee for Clinical Pharmacology      Member

Veterans Administration System

06/1995-06/2010      Federal Government      US Pharmacopeia Advisory Panel on Geriatrics  
Member

06/1995-06/2000 Cardiovascular Drugs	Federal Government Member	US Pharmacopeia; Advisory Committee on	
06/1992-06/1996 Committee	Federal Government Member	Cardiovascular and Renal Drugs Advisory Food and Drug Administration	
06/1985-06/2010	Federal Government	U S Pharmacopeia	Other
Delegate from UTHSCSA			
06/1985-06/2010 Advisory Panel	Federal Government Member	US Pharmacopeia General Drug Information Division	
06/1982-06/1983 Program	Federal Government Member	Veterans Administration Physicians In-Residence	

**SERVICE TO THE INSTITUTION:**

Dates	Type	Description
6/1983-Present	University Hospital	Pharmacy & Therapeutics Committee Role: Chair
01/1983-12/2012	Department	Staff and Personnel laterally supervised: Kathy Morren, RN, Research Nurse III Laura Freeman, Health Care Counselor II Yolanda Colunga, Administrative Assistant II Role: Director
06/1980-Present	Hospital	Medicine Hypertension Service Role: Director
01/1981-Present	Department	Clinical Pharmacology Selective Role: Director
06/1983-08/2012	Department of Medicine	Division of Clinical Pharmacology Role: Division Chief
06/1964-06/1965	University	St. Andrews University Students Role: Council Member



**SERVICE TO THE PROFESSION:**

Dates	Type	Description
01/2000-01/2001	National	American Society for Clinical Pharmacology and Therapeutics Role: Vice Chairman Finance Committee
06/1999-Present	National	National Medical Advisory Panel for Pharmacy Benefits Management Role: Member. Veterans Administration
01/1999-01/2000	National	American Society for Clinical Pharmacology and Therapeutics Finance Committee Role: Member
06/1996-06/2010	National	Clinical Pharmacology and Therapeutics Role: Editorial Board Member
06/1994-06/2002	National	The American Journal of the Medical Sciences Role: Editorial Board Member
06/1992-06/2010	National	The Medical Sciences - Clinical Pharmacology Forum Role: Member
06/1992-2017	National	American Board of Clinical Pharmacology Role: Executive Director
01/1992-06/2010	National	Journal of the American Medical Association Role: Reviewer
01/1992-06/2010	National	Archives of Internal Medicine Role: Reviewer
01/1992-01/1996	National	American Society for Pharmacology and Experimental Therapeutics. Division for Clinical Pharmacology Role: Member Executive Committee
01/1992-01/1993	National	American Society for Clinical Pharmacology and Therapeutics Role: President
06/1991-06/1992	National	Ethics Committee , American Society for Clinical Pharmacology and Therapeutics Role: Member

06/1991-06/1992	National	Finance Committee, American Society for Clinical Pharmacology and Therapeutics Role: Member
06/1991-06/1992	National	Publications Committee Member, American Society for Clinical Pharmacology and Therapeutics Role: Member
06/1991-06/1992	National	Scientific Program Committee, American Society for Clinical Pharmacology and Therapeutics Role: Member
01/1991-06/2002	National	Microvascular Research Role: Reviewer
01/1991-01/1992	National	American Society for Clinical Pharmacology and Therapeutics Role: President-Elect
01/1991-01/1992	National	American Society for Clinical Pharmacology and Therapeutics Role: Chair, Nominating Committee
06/1990-06/1991	National	Clinical Pharmacology Division Executive Committee American Society for Pharmacology and Experimental Therapeutics Role: Member
01/1990-06/1998	International	European Journal of Clinical Pharmacology Role: Reviewer
01/1990-01/1991	National	Executive Committee, Clinical Pharmacology Division of the American Society for Pharmacology and Experimental Therapeutics Role: Member
01/1990-01/1991	National	American Society for Clinical Pharmacology and Therapeutics Role: Vice-President
01/1990-04/1990	National	Scientific Program Committee, American Society for Clinical Pharmacology and Therapeutics Role: Chair
06/1989-06/1992	National	American Board of Clinical Pharmacology Role: Chair
06/1989 - 2017	National	American Board of Clinical Pharmacology Role: Executive Committee Member
01/1989-06/2010	National	Clinical Pharmacology and Therapeutics

		Role: Reviewer
01/1989-04/1989	National	Scientific Committee , American Society for Clinical Pharmacology and Therapeutics National Meeting
06/1988-06/1990	National	Executive Committee, American Society for Clinical Pharmacology and Therapeutics Role: Member
06/1987-06/1992	National	Journal of Cardiovascular Pharmacology Role: Editorial Board Member
06/1987-06/1991	National	American Society for Clinical Pharmacology and Therapeutics Role: Board of Directors
01/1987-01/1990	National	Medical Education Committee, American Society for Clinical Pharmacology and Therapeutics Role: Member
01/1987-12/1987	National	Ad Hoc Committee on Drugs in the Elderly American Society for Clinical Pharmacology and Therapeutics Role: Member
01/1987-12/1987	National	Scientific Program Committee American Society for Clinical Pharmacology and Therapeutics Role: Member
01/1986-01/1989	National	Council on Clinical Pharmacology Role: Member
01/1986-12/1986	National	Nominating Committee American Society for Clinical Pharmacology and Therapeutics Role: Member
01/1984-01/1989	National	Liaison Committee to the Council on Clinical Pharmacology American Society of Clinical Pharmacology and Therapeutics Role: Member
01/1984-01/1989	State	Central Research Review Committee American Heart Association, Texas Affiliate Role: Member
06/1982-06/1995	National	Substance and Alcohol Use/Abuse Role: Editorial Board Member

**SERVICE TO THE PUBLIC:**

Since 2015, I have served as judge in 2-3 High School Science fairs in Texas each year. Some local High Schools, some State-wide, some regional in San Antonio.

04/2014-04/2015	Judge, 2014 Exxon Mobil Texas Science and Engineering Fair
04/2013-04/2013	Judge, 2013 Exxon Mobil Texas Science and Engineering Fair
04/2012-04/2012	Judge, 2012 Exxon Mobil Texas Science and Engineering Fair
04/2011-04/2011	Judge, 2011 ExxonMobil Texas Science and Engineering Fair
03/2011-03/2011	Judge, Alamo Regional Academy of Science and Engineering
12/2010-12/2010	Judge, Harmony Science Academy 5th Annual Science & Engineering Fair
04/2010-04/2010	Judge, Harmony Science Academy, San Antonio
04/2010-04/2010	Judge, 2010 Exxon Mobil Texas Science and Engineering Fair
03/2010-03/2010	Judge, 2010 Exxon Mobil Texas Science and Engineering Fair
03/2010-03/2010	Judge, Alamo Regional Academy of Science and Engineering
12/2009-12/2009	Judge, 4th Annual Science Fair & Engineering fair, Harmony Science Academy-San Antonio
03/2009-03/2009	Judge, 2009 Exxon Mobil Texas Science and Engineering Fair
04/2008-04/2008	Judge,2008 Exxon Mobil Texas Science and Engineering Fair
04/2007-04/2007	Judge,2007 Exxon Mobil Texas Science and Engineering Fair
03/2006-03/2006	Judge, Alamo Regional Academy of Science and Engineering
03/2005-03/2005	Judge, Alamo Regional Academy of Science and Engineering
06/1992-06/1994	Founding member of PTA, Keystone School
06/1990-06/1996	Treasurer, Board of Governors, Keystone School
06/1990-06/1996	Vice Chairman, Board of Governors, Keystone School
06/1964-06/1965	Representative to British Medical Student Association

**PROFESSIONAL AFFILIATIONS:**

Dates	Organization
11/2005-11/2010	U.S. Pharmacopeia. Volunteer vice-chair of the Cardiology Expert Committee
06/1987-Present	American Board of Clinical Pharmacology
06/1987-2018	American Society of Hypertension
06/1983-Present	American Society for Clinical Pharmacology and Therapeutics
06/1983-Present	Council for High Blood Pressure Research, American Heart Association
06/1981-06/2010	American Society for Pharmacology and Experimental Therapeutics
06/1981-Present	Southern Society for Clinical Investigation
06/1978-06/2010	American Federation for Clinical Research
06/1975-06/1978	Medical Research Society for Great Britain
06/1975-06/1978	Scottish Society for Experimental Medicine
06/1972-Present	Royal College of Physicians of the United Kingdom

**COMMITTEES (UTHSCSA Standing Committees):**DEPARTMENT

Dates	Committee	Role
04/2007-03/2011	Post-Tenure Review Committee	Member

SCHOOL

01/1972-12/1972	Pre-Clinical Promotions Committee	Alternate
-----------------	-----------------------------------	-----------

**COMMITTEES (OTHER):**HOSPITAL

Dates	Committee	Role
06/1984-06/1994	GCRC Committee, South Texas Veterans Health Care Network, Audie L. Murphy Division	Member
06/1983-06/2002	Pharmacy and Therapeutics Committee, South Texas Veterans Health Care Network, Audie L. Murphy Division	Chair
06/1983-06/2002	Quality Assurance Committee, South Texas Veterans Health Care Network, Audie L. Murphy Division	Member
06/1983-Present	Pharmacy and Therapeutics Committee, University Hospital District	Chair
06/1982-06/1983	Pharmacy and Therapeutics Committee, South Texas Veterans Health Care Network, Audie L. Murphy Division	Member
06/1980-06/1982	Pharmacy and Therapeutics Committee, University Hospital District	Member

OTHER

Dates	Committee	Role
06/1986-06/2010	South Texas Geriatric Education Center	Faculty Advisory Board

SCHOOL

Dates	Committee
06/1982-Present	Medical Student Faculty Advisor, UTHSCSA, Medical School

## UNIVERSITY

Dates	Committee	
08/2007-06/2010	Committee on Clinician-Industry Interactions, UTHSCSA Role: Member	
09/2006-08/2007	Campus Health and Wellness Committee, UTHSCSA Role: Member	
06/1993-06/1994	Industry/University Cooperative Research Center, UTHSCSA Role: Faculty Advisory Board (ex officio)	
06/1987-06/1991	South Texas Medical Center Research Building Committee, UTHSCSA Role: Member	
06/1987-06/1989	President's Committee on University Presence in the Research Park, UTHSCSA Role: Member	
06/1982-06/1985	Institutional Review Board	Member